Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Zora Neskovic-Konstantinovic

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus as First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Journal of Clinical Oncology

English

Estrogen-Regulated Proteins Cathepsin D and pS2 in Breast Carcinoma

English

Related publications

Efficacy of First-Line Letrozole Versus Tamoxifen as a Function of Age in Postmenopausal Women With Advanced Breast Cancer

English

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Journal of Clinical Oncology

English

Phase I/Ii Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)

English

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide as Primary Systemic Treatment in Elderly Breast Cancer Patients

Journal of Clinical Oncology

English

Palbociclib With Letrozole in Postmenopausal Women With ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial

English

Lapatinib Plus Capecitabine in Women With HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

English

Design, Conduct, and Analyses of Breast International Group (BIG) 1-98: A Randomized, Double-Blind, Phase-Iii Study Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor-Positive, Early Breast Cancer

English

Design of RESILIENCE: A Phase 3 Trial Comparing Capecitabine in Combination With Sorafenib or Placebo for Treatment of Locally Advanced or Metastatic HER2-negative Breast Cancer

Breast Cancer Research

Cancer Research

Oncology

2011

English

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Clinical Breast Cancer

Cancer Research

Oncology

2014

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Zora Neskovic-Konstantinovic

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus as First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Estrogen-Regulated Proteins Cathepsin D and pS2 in Breast Carcinoma

Related publications

Efficacy of First-Line Letrozole Versus Tamoxifen as a Function of Age in Postmenopausal Women With Advanced Breast Cancer

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Phase I/Ii Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide as Primary Systemic Treatment in Elderly Breast Cancer Patients

Palbociclib With Letrozole in Postmenopausal Women With ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial

Lapatinib Plus Capecitabine in Women With HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

Design, Conduct, and Analyses of Breast International Group (BIG) 1-98: A Randomized, Double-Blind, Phase-Iii Study Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor-Positive, Early Breast Cancer

Design of RESILIENCE: A Phase 3 Trial Comparing Capecitabine in Combination With Sorafenib or Placebo for Treatment of Locally Advanced or Metastatic HER2-negative Breast Cancer

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer